More serious risks - including pancreatitis and thyroid-related concerns - are documented in FDA-approved GLP-1 prescribing information
That said, reassurance is not the same as dismissal
It's based on clinical data and real user timelines
In parallel with the development of standardised methods for experimental testing, there is an urgent need to establish robust protocols for the analysis of human samples and the accurate quantification of MNPs levels in consumer products and environmental matrices, as these are crucial for defining human-relevant doses in toxicological studies
Combining your genetic insights with your provider's clinical assessmentBMI, metabolic markers, cardiovascular health, and medication historycreates a more complete picture for personalized treatment planning
International Heart Journal, 58 (5), 778786